08:00 , Feb 1, 2010 |  BC Week In Review  |  Company News

b3 bio Inc., Roche deal

Roche and b3 bio will develop preclinical technologies for undisclosed indications. Roche will increase its equity holding in b3 bio and have rights to technologies developed under the deal. Further terms were not disclosed. b3...